avkАрхивъ внутренней медициныThe Russian Archives of Internal Medicine2226-67042411-6564“SINAPS” LLC10.20514/2226-6704-2026-16-1-12-19FFWTVJavk-2163Research ArticleОБЗОРНЫЕ СТАТЬИREVIEW ARTICLESКраткий обзор истории развития фармакологической антигипертензивной терапииA Brief Overview of The History of The Development of Pharmacological Antihypertensive Therapyhttps://orcid.org/0009-0002-1297-5035ВедерниковА. А.VedernikovA. A.

Ведерников Артем Андреевич — врач — кардиолог, кардиологического отделения № 2

Тюмень

Artyom A. Vedernikov — MD, cardiologist, cardiology department No. 2

Tyumen

barterer55@yandex.ruhttps://orcid.org/0000-0002-6086-4578МежоновЕ. М.MezhonovЕ. М.

Межонов Евгений Михайлович — д.м.н., профессор кафедры кардиологии и кардиохирургии с курсом скорой помощи Института клинической медицины, врач-кардиолог

Тюмень

Evgeny M. Mezhonov — MD, D. Sci. (Med.), Professor of the Department of Cardiology and Cardiac Surgery with an Emergency Care Course at the Institute of Clinical Medicine, cardiologist

Tyumen

https://orcid.org/0009-0009-3201-382XВедерниковаС. А.VedernikovaS. A.

Ведерникова Софья Андреевна — аспирант кафедры госпитальной терапии с курсом эндокринологии Института клинической медицины

Тюмень

Sofya A. Vedernikova — postgraduate student of the Department of Hospital Therapy with a course in Endocrinology

Tyumen

https://orcid.org/0000-0001-6470-5606ВялкинаЮ. А.VyalkinaYu. A.

Вялкина Юлия Александровна — к.м.н., доцент кафедры госпитальной терапии с курсом эндокринологии Института клинической медицины

Тюмень

Yulia A. Vyalkina — PhD, Associate Professor of the Department of Hospital Therapy with a Course in Endocrinology of the Institute of Clinical Medicine

Tyumen

Областная клиническая больница № 1РоссияRegional Clinical Hospital No1Russian FederationОбластная клиническая больница № 1 ; ФГБОУ ВО Тюменский ГМУ Минздрава РоссииРоссияRegional Clinical Hospital No1 ; Federal State Budgetary Educational Institution of Higher Education «Tyumen State Medical University» of the Ministry of Healthcare of the Russian FederationRussian FederationФГБОУ ВО Тюменский ГМУ Минздрава РоссииРоссияFederal State Budgetary Educational Institution of Higher Education «Tyumen State Medical University» of the Ministry of Healthcare of the Russian FederationRussian Federation2026050220261611219Copyright © Ведерников А.А., Межонов Е.М., Ведерникова С.А., Вялкина Ю.А., 20262026Ведерников А.А., Межонов Е.М., Ведерникова С.А., Вялкина Ю.А.Vedernikov A.A., Mezhonov Е.М., Vedernikova S.A., Vyalkina Y.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.medarhive.ru/jour/article/view/2163

На протяжении многих десятилетий сердечно-сосудистые заболевания занимают лидирующую позицию в структуре смертности во всем мире. Имеются данные, что общее число сердечно-сосудистых заболеваний удвоилось за последние 30 лет, а число смертей от них выросло на 65 % за это же время. Вместе с тем увеличивающаяся распространенность артериальной гипертензии как важнейшего фактора риска сердечно-сосудистых заболеваний представляет собой глобальную проблему всемирного здравоохранения. В такой ситуации актуален вопрос антигипертензивной терапии, её качества. Сохраняется потребность в дальнейших исследованиях новых классов антигипертензивных препаратов. В статье кратко обсуждается эволюция взглядов на патогенез артериальной гипертензии, поэтапное внедрение в широкую клиническую практику препаратов, снижающих артериальное давление. Также в статье приведены новые группы препаратов и последние тенденции в лечении артериальной гипертензии.

For many decades, cardiovascular diseases have been the leading cause of death worldwide. There is evidence that the total number of cardiovascular diseases has doubled over the past 30 years, and the number of deaths from them has steadily increased by 65 % over the same time. At the same time, the increasing prevalence of arterial hypertension as the most important risk factor for cardiovascular diseases is a global problem for world health. In this situation, the issue of antihypertensive therapy and its quality is relevant. There is still a need for further research into new classes of antihypertensive drugs. The article briefly discusses the evolution of views on the pathogenesis of arterial hypertension, the gradual introduction of drugs that lower blood pressure into widespread clinical practice. The article also presents new groups of drugs and the latest trends in the treatment of arterial hypertension.

история медициныкардиологиягипертоническая болезньантигипертензивные препаратыhistory of medicinecardiologyhypertensionantihypertensive drugsReferencesBooth J. A short history of blood pressure measurement. Proc R SocMed. 1977;70(11):793-799.Booth J. A short history of blood pressure measurement. Proc R SocMed. 1977;70(11):793-799.Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):1269-1324. doi: 10.1161/HYP.0000000000000066Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):1269-1324. doi: 10.1161/HYP.0000000000000066Фогельсон Л.И. Болезни сердца и сосудов. М.: Государственное издательство биологической и медицинской литературы; 1935; 120 с.Fogelson L.I. Diseases of the heart and blood vessels. M.: State Publishing House of Biological and Medical Literature; 1935 ; 120 р. [in Russian].Плетнев Д.Д. Гипертония (опыт анализа ее генеза). Пульмонология. 2022;32(2 (Прил)):22-26. doi: 10.18093/0869- 0189-2022-32-2S-22-26Pletnev D.D. Hypertension (experience of analyzing its genesis). Pulmonologiya. 2022; 32 (2, Suppl.): 22–26. doi: 10.18093/0869-0189-2022-32-2S-22-26 [in Russian].Ланг Г.Ф. Гипертоническая болезнь. Л.: Медгиз; 1950; 353 с.Lang G.F. Hypertension. L.: Medgiz; 1950; 353 р. [in Russian].Азимов А. Краткая история химии /Пер. с англ. В.М. Абашкина. М.: ЗАО Центрполиграф; 2002; 106 с.Azimov A. A brief history of chemistry /Trans. from English V.M. Abashkina. M.: ZAO Tsentrpoligraf; 2002; 106 р. [in Russian].Glazer G, Myers KA, Davies ER. Ergot poisoning. Postgrad Med J. 1966;42(491):562-568. doi: 10.1136/pgmj.42.491.562Glazer G, Myers KA, Davies ER. Ergot poisoning. Postgrad Med J. 1966;42(491):562-568. doi: 10.1136/pgmj.42.491.562ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensinconverting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) [published correction appears in JAMA 2003 Jan 8;289(2):178] [published correction appears in JAMA. 2004 May 12;291(18):2196]. JAMA. 2002;288(23):2981-2997. doi: 10.1001/jama.288.23.2981ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensinconverting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) [published correction appears in JAMA 2003 Jan 8;289(2):178] [published correction appears in JAMA. 2004 May 12;291(18):2196]. JAMA. 2002;288(23):2981-2997. doi: 10.1001/jama.288.23.2981Nikolic K, Agbaba D. Imidazoline antihypertensive drugs: selective i(1) -imidazoline receptors activation. Cardiovasc Ther. 2012;30(4):209-216. doi: 10.1111/j.1755-5922.2011.00269.xNikolic K, Agbaba D. Imidazoline antihypertensive drugs: selective i(1) -imidazoline receptors activation. Cardiovasc Ther. 2012;30(4):209-216. doi: 10.1111/j.1755-5922.2011.00269.xEpinephrin from the Suprarenal Capsule: “A Classic of Science.” (1932). The Science News-Letter, 22(610), 391–392. doi: 10.2307/3908203Epinephrin from the Suprarenal Capsule: “A Classic of Science.” (1932). The Science News-Letter, 22(610), 391–392. doi: 10.2307/3908203Powell CE, Slater IH. Blocking of inhibitory adrenergic receptors by a dichloro analog of isoproterenol. J Pharmacol Exp Ther. 1958;122(4):480-488.Powell CE, Slater IH. Blocking of inhibitory adrenergic receptors by a dichloro analog of isoproterenol. J Pharmacol Exp Ther. 1958;122(4):480-488.Black JW, Crowther AF, Shanks RG, Smith LH, Dornhorst AC. A new adrenergic betareceptor antagonist. Lancet. 1964;1(7342):1080-1081. doi: 10.1016/s0140-6736(64)91275-9Black JW, Crowther AF, Shanks RG, Smith LH, Dornhorst AC. A new adrenergic betareceptor antagonist. Lancet. 1964;1(7342):1080-1081. doi: 10.1016/s0140-6736(64)91275-9Frishman W.H., Charlap S. Alpha-and beta-adrenergic blocking drugs //Cardiovascular Pharmacotherapeutics. New York, NY: McGraw-Hill. 2003; 67-97.Frishman W.H., Charlap S. Alpha-and beta-adrenergic blocking drugs //Cardiovascular Pharmacotherapeutics. New York, NY: McGraw-Hill. 2003; 67-97.Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A metaanalysis. Lancet. 2005;366(9496):1545-1553. doi: 10.1016/S0140-6736(05)67573-3Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A metaanalysis. Lancet. 2005;366(9496):1545-1553. doi: 10.1016/S0140-6736(05)67573-3Hollman A. Plants in cardiology. BMJ, 1992. 40. doi: 10.1136/hrt.67.5.376Hollman A. Plants in cardiology. BMJ, 1992. 40. doi: 10.1136/hrt.67.5.376SoRelle R. Withdrawal of Posicor from market. Circulation. 1998;98(9):831-832. doi: 10.1161/01.cir.98.9.831SoRelle R. Withdrawal of Posicor from market. Circulation. 1998;98(9):831-832. doi: 10.1161/01.cir.98.9.831Friedel HA, Brogden RN. Pinacidil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension. Drugs. 1990;39(6):929-967. doi: 10.2165/00003495-199039060-00008Friedel HA, Brogden RN. Pinacidil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension. Drugs. 1990;39(6):929-967. doi: 10.2165/00003495-199039060-00008Stevens CD, Kotte JH. The treatment of human hypertension with a kidney extract. Am J Med Sci. 1946;211:227-231.Stevens CD, Kotte JH. The treatment of human hypertension with a kidney extract. Am J Med Sci. 1946;211:227-231.Page, Taylor, Corcoran a. others. Correlation of clinical types of hypertension with renal function. Ill. Effect of spinal anaesthesia. J. A. M. A., 124, 185, 1944.Page, Taylor, Corcoran a. others. Correlation of clinical types of hypertension with renal function. Ill. Effect of spinal anaesthesia. J. A. M. A., 124, 185, 1944.Ferreira SH. A Bradykinin-potentiating factor (bpf) present in the venom of bothrops jararca. Br J Pharmacol Chemother. 1965;24(1):163-169. doi: 10.1111/j.1476-5381.1965.tb02091.xFerreira SH. A Bradykinin-potentiating factor (bpf) present in the venom of bothrops jararca. Br J Pharmacol Chemother. 1965;24(1):163-169. doi: 10.1111/j.1476-5381.1965.tb02091.xBurnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet. 2000;355(9204):637-645. doi: 10.1016/s0140-6736(99)10365-9Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet. 2000;355(9204):637-645. doi: 10.1016/s0140-6736(99)10365-9Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367(23):2204-2213. doi: 10.1056/NEJMoa1208799Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367(23):2204-2213. doi: 10.1056/NEJMoa1208799Богданов Д.В., Шишминцева Е.П. Особенности терапии артериальной гипертензии на врачебном участке. Медицинская наука и образование Урала. 2023. Т.24,№ 1; 11-14. doi: 10.36361/18148999_2023_24_1_11Богданов Д.В., Шишминцева Е.П. Особенности терапии артериальной гипертензии на врачебном участке. Медицинская наука и образование Урала. 2023. Т.24,№ 1; 11-14. doi: 10.36361/18148999_2023_24_1_11 Bogdanov DV, Shishmintseva EP. Peculiarities of therapy of arterial hypertension in the medical site. Medical science and education of Ural. 2023. Vol.24, no.1; 11-14. doi: 10.36361/18148999_2023_24_1_11 [in Russian].Williams B, Cockcroft JR, Kario K, et al. Effects of Sacubitril/ Valsartan Versus Olmesartan on Central Hemodynamics in the Elderly With Systolic Hypertension: The PARAMETER Study. Hypertension. 2017;69(3):411-420. doi: 10.1161/HYPERTENSIONAHA.116.08556Williams B, Cockcroft JR, Kario K, et al. Effects of Sacubitril/ Valsartan Versus Olmesartan on Central Hemodynamics in the Elderly With Systolic Hypertension: The PARAMETER Study. Hypertension. 2017;69(3):411-420. doi: 10.1161/HYPERTENSIONAHA.116.08556Roth GA, Mensah GA, Johnson CO, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study [published correction appears in J Am Coll Cardiol. 2021 Apr 20;77(15):1958-1959. doi: 10.1016/j.jacc.2021.02.039.]. J Am Coll Cardiol. 2020;76(25):2982-3021. doi: 10.1016/j.jacc.2020.11.010Roth GA, Mensah GA, Johnson CO, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study [published correction appears in J Am Coll Cardiol. 2021 Apr 20;77(15):1958-1959. doi: 10.1016/j.jacc.2021.02.039.]. J Am Coll Cardiol. 2020;76(25):2982-3021. doi: 10.1016/j.jacc.2020.11.010Dogra S, Shah S, Gitzel L, et al. Baxdrostat: A Novel Aldosterone Synthase Inhibitor for Treatment Resistant Hypertension. Curr Probl Cardiol. 2023;48(11):101918. doi: 10.1016/j.cpcardiol.2023.101918Dogra S, Shah S, Gitzel L, et al. Baxdrostat: A Novel Aldosterone Synthase Inhibitor for Treatment Resistant Hypertension. Curr Probl Cardiol. 2023;48(11):101918. doi: 10.1016/j.cpcardiol.2023.101918Bakris GL, Saxena M, Gupta A, et al. RNA Interference With Zilebesiran for Mild to Moderate Hypertension: The KARDIA-1 Randomized Clinical Trial. JAMA. 2024;331(9):740-749. doi: 10.1001/jama.2024.0728Bakris GL, Saxena M, Gupta A, et al. RNA Interference With Zilebesiran for Mild to Moderate Hypertension: The KARDIA-1 Randomized Clinical Trial. JAMA. 2024;331(9):740-749. doi: 10.1001/jama.2024.0728Freeman MW, Halvorsen YD, Marshall W, et al. Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension. N Engl J Med. 2023;388(5):395-405. doi: 10.1056/NEJMoa2213169Freeman MW, Halvorsen YD, Marshall W, et al. Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension. N Engl J Med. 2023;388(5):395-405. doi: 10.1056/NEJMoa2213169Trensz F, Bortolamiol C, Kramberg M, et al. Pharmacological Characterization of Aprocitentan, a Dual Endothelin Receptor Antagonist, Alone and in Combination with Blockers of the Renin Angiotensin System, in Two Models of Experimental Hypertension. J Pharmacol Exp Ther. 2019;368(3):462-473. doi: 10.1124/jpet.118.253864Trensz F, Bortolamiol C, Kramberg M, et al. Pharmacological Characterization of Aprocitentan, a Dual Endothelin Receptor Antagonist, Alone and in Combination with Blockers of the Renin Angiotensin System, in Two Models of Experimental Hypertension. J Pharmacol Exp Ther. 2019;368(3):462-473. doi: 10.1124/jpet.118.253864

The authors declare that there are no conflicts of interest present.